Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Derivatives -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (113)	4/20/1999 12:09:00 PM
From: LLCF	Read Replies (1) \| Respond to of 555

<BTW.... abstracts pointing to this were posted in the relevant thread prior to the meeting. > Yes, I had seen that thankyou... just a bit confusing the way the companies "spin" this stuff. I agree with your point... why say that if it hurts credibility... just eat some crow and go ahead and develope the product... who cares if your original thesis (?) didn't pan out "exactly"? DAK PS... bidding 4 5/16 for some more NBIX today....

To: scaram(o)uche who wrote (113)	4/20/1999 2:49:00 PM
From: SnowShredder	Read Replies (1) \| Respond to of 555

The thing to worry about with Onyx-O15 is that if this isn't true... >>defective p53 signal is required for replication<< and a defective p53 signal is not necessary then their patent protection may be in danger...since their mutant virus would b a slower replicating Ad vs. wt. So for treatment of cancer it might be more beneficial to just to use a wt Ad instead, since the faster replication will lyse the infected cells sooner...increasing the amount of viral spread & tumor shrinkage before the immune response really kicks in. Then why would it be more beneficial to use the mutant virus? (JMHO)...Best of Luck, Where'd He Go?